Rafal Dziadziuszko
Overview
Explore the profile of Rafal Dziadziuszko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
173
Citations
5688
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahn M, Cho B, Felip E, Korantzis I, Ohashi K, Majem M, et al.
Future Oncol
. 2024 Nov;
20(40):3355-3364.
PMID: 39530627
What Is This Summary About?: This is a summary of a phase 2 clinical study called DeLLphi-301. The study looked at how effective and safe a medicine called tarlatamab was...
2.
Wenta R, Richert J, Muchlinska A, Senkus E, Suchodolska G, Lapinska-Szumczyk S, et al.
Cytometry A
. 2024 Nov;
105(12):883-892.
PMID: 39498617
Liquid biopsies developed into a range of sensitive technologies aiming to analyze for example, circulating tumor cells (CTCs) in peripheral blood, which significantly deepens understanding of the metastatic process. Nevertheless,...
3.
Verlingue L, Italiano A, Prenen H, Alia E, Tosi D, Perets R, et al.
EBioMedicine
. 2024 Oct;
109:105374.
PMID: 39395231
Background: Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment. We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in...
4.
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, et al.
Lung Cancer
. 2024 Sep;
196:107924.
PMID: 39306923
Objectives: IMbrella A is a Phase III extension study that allowed rollover from Roche/Genentech-sponsored atezolizumab trials, including IMpower133, a Phase I/III trial of first-line atezolizumab or placebo plus carboplatin/etoposide in...
5.
Dziadziuszko R, Tomasik B
Lancet Respir Med
. 2024 Sep;
12(12):941-943.
PMID: 39305911
No abstract available.
6.
Janzic U, Maimon Rabinovich N, Shalata W, Kian W, Szymczak K, Dziadziuszko R, et al.
Curr Oncol
. 2024 Aug;
31(8):4369-4381.
PMID: 39195309
ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs....
7.
Dziadziuszko R, Rzyman W
J Clin Oncol
. 2024 Jul;
42(26):3071-3072.
PMID: 39042841
No abstract available.
8.
Peters S, Gadgeel S, Mok T, Nadal E, Kilickap S, Swalduz A, et al.
Nat Med
. 2024 Jun;
30(7):1923-1932.
PMID: 38898120
Although comprehensive biomarker testing is recommended for all patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line treatment, tissue availability can limit testing. Genomic testing in liquid...
9.
Levy A, Adebahr S, Hurkmans C, Ahmed M, Ahmad S, Guckenberger M, et al.
J Thorac Oncol
. 2024 May;
19(9):1297-1309.
PMID: 38788924
Introduction: The international phase II single-arm LungTech trial 22113-08113 of the European Organization for Research and Treatment of Cancer assessed the safety and efficacy of stereotactic body radiotherapy (SBRT) in...
10.
Chaft J, Dziadziuszko R, Haddock Lobo Goulart B
Am Soc Clin Oncol Educ Book
. 2024 May;
44(3):e432500.
PMID: 38788177
Clinical investigation of immune checkpoint inhibitors (ICIs) has expanded from indications in metastatic non-small cell lung cancer (NSCLC) to add to the treatment of early-stage or resectable NSCLC. Although completed...